Infectious Disease

Treponema pallidum total antibodies
Total automation for syphilis screening
**Infectious Disease**

**Syphilis screening?**

**LIAISON® Treponema screen is the solution**

**Clinical background**

Syphilis is a chronic infectious disease caused by sexual or congenital transmission of the *Treponema pallidum spirochete*, which remains a global problem with an estimated 12 million people infected each year, despite the existence of effective prevention measures and effective and relatively inexpensive treatment options. Serological testing is essential in the detection and control of syphilis infection.

The 2008 European IUSTI/WHO recommendations suggest the treponemal antigen-based Enzyme/Chemiluminescence immunoassays or TPPA (preferred to TPHA) as appropriate as a single screening test. The RPR/VDRL is not recommended as a primary screening test. The Confirmatory test if any primary screening test is positive should be a treponemal antigen test of a different type from the primary screening test recommended.1

---

**IUSTI/WHO 2008 recommendations**

- **EIA/CLIA/TPPA**
  - **EIA/CLIA/TPPA**
    - **Confirmatory with different type of treponemal test**
    - **EIA/CLIA/TPPA**
    - **Quantitative TPPA**
    - **Test for serological activity of Syphilis quantitative RPR/VDRL**
    - **Test for monitoring the serological response to treatment quantitative RPR/VDRL**

**CDC-recommended algorithm for reverse sequence syphilis screening**

- **EIA or CLIA**
  - **EIA or CLIA**
    - **Quantitative RPR or other non-treponemal test**
    - **RPR**
      - **TPPA**
        - **TPPA Syphilis (past or present)**
        - **TPPA Syphilis unlikely**

---

**Main Features**

- Number of tests: 200
- Solid phase & conjugate: recombinant antigens
- Label: Isoluminol derivative
- Method: one-step sandwich chemiluminescence immunoassay (CLIA)

**Ordering information**

**LIAISON® Treponema Screen (code 310840)**

**LIAISON® Control Treponema Screen (code 310841)**

**Quick and reliable results made possible by flexibility**

- **Diagnostic Specificity**: 99.91% (95% C.I.: 99.75 - 99.98%)
- **Diagnostic Sensitivity**: 99.40% (95% C.I.: 96.73 - 99.98%)
- **Reagent stability on board**: minimum 4 weeks or more if controls are found within the expected ranges

---

**Abbreviations:**

- EIA/CLIA = enzyme immunoassay/chemiluminescence immunoassay; RPR = rapid plasma reagin; TPPA = Treponema pallidum particle agglutination; VDRL = Venereal Disease Research Laboratory.
- † If incubating or primary syphilis is suspected, treat with benzathine penicillin G 2.4 million units intramuscularly in a single dose.
- ¶ If at risk for syphilis, repeat RPR in several weeks.

---

**Ordering information**

**LIAISON® Treponema Screen (code 310840)**

**LIAISON® Control Treponema Screen (code 310841)**

**Available on LIAISON® Systems**

Product availability subject to required regulatory approvals

---

**DiaSorin S.p.A.**
Via Crescenzio
13040 Saluggia (VC) - Italy
Tel. +39.0161.487526
Fax: +39.0161.487670
www.diasorin.com
E-mail: info@diasorin.it

**DiaSorin**
The Diagnostic Specialist